Phase IIT Trial of SNA014

Launched by SMARTNUCLIDE BIOPHARMA · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Phase IIT Trial of SNA014, is exploring a new imaging technique for patients with specific types of cancer, including stomach adenocarcinoma, gastroesophageal junction adenocarcinoma, and pancreatic cancer. The trial will use a special contrast agent labeled with a radioactive material (68Ga) that helps doctors see cancer cells more clearly during PET/CT scans. This could help improve how these cancers are diagnosed and treated.

To be eligible for the trial, participants must be between 18 and 75 years old and have been diagnosed with one of the cancers mentioned. They should also have had recent medical imaging or tests related to their condition. However, people with other active cancers, uncontrolled infections, or serious health issues may not qualify for this study. The trial is not yet recruiting participants, but once it starts, those who join can expect to undergo imaging tests to help researchers understand how well this new imaging agent works in identifying cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age range of 18 to 75 years old (including boundary values);
• • Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
• • Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
• • Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
• • Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).
• Exclusion Criteria:
• * Merge patients with other clearly diagnosed malignant tumors:
• • Uncontrolled severe infections or individuals with other serious illnesses;
• • Those with an expected survival period of less than or equal to three months;
• • Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;
• • investigators determine that patients who are not suitable to participate in this study;